nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.803	1	CiPCiCtD
Ruxolitinib—PLK1—Sorafenib—Vismodegib—skin cancer	0.00149	1	CbGdCrCtD
Ruxolitinib—CYP3A4—Temozolomide—skin cancer	0.00128	0.292	CbGbCtD
Ruxolitinib—CYP3A4—Imiquimod—skin cancer	0.00128	0.292	CbGbCtD
Ruxolitinib—Myelosuppression—Bleomycin—skin cancer	0.00123	0.0289	CcSEcCtD
Ruxolitinib—Haemorrhage intracranial—Temozolomide—skin cancer	0.00119	0.0278	CcSEcCtD
Ruxolitinib—Myelosuppression—Dactinomycin—skin cancer	0.00115	0.0269	CcSEcCtD
Ruxolitinib—Herpes zoster—Imiquimod—skin cancer	0.00108	0.0253	CcSEcCtD
Ruxolitinib—JAK1—hair follicle—skin cancer	0.00104	0.0158	CbGeAlD
Ruxolitinib—Myelosuppression—Temozolomide—skin cancer	0.00104	0.0243	CcSEcCtD
Ruxolitinib—Myelosuppression—Fluorouracil—skin cancer	0.000957	0.0224	CcSEcCtD
Ruxolitinib—CAMK2G—nerve—skin cancer	0.000932	0.0141	CbGeAlD
Ruxolitinib—CLK2—hair follicle—skin cancer	0.000926	0.014	CbGeAlD
Ruxolitinib—LRRK2—nerve—skin cancer	0.000923	0.014	CbGeAlD
Ruxolitinib—PLK3—nipple—skin cancer	0.000921	0.0139	CbGeAlD
Ruxolitinib—CYP3A4—Vismodegib—skin cancer	0.000889	0.202	CbGbCtD
Ruxolitinib—Weight decreased—Vismodegib—skin cancer	0.000876	0.0205	CcSEcCtD
Ruxolitinib—DYRK1A—hair follicle—skin cancer	0.000875	0.0132	CbGeAlD
Ruxolitinib—CAMK1—nipple—skin cancer	0.000861	0.013	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Imiquimod—skin cancer	0.000859	0.0201	CcSEcCtD
Ruxolitinib—Bone pain—Imiquimod—skin cancer	0.000849	0.0199	CcSEcCtD
Ruxolitinib—BMPR2—blood vessel—skin cancer	0.000818	0.0124	CbGeAlD
Ruxolitinib—PLK1—skin of body—skin cancer	0.000707	0.0107	CbGeAlD
Ruxolitinib—JAK1—nipple—skin cancer	0.000707	0.0107	CbGeAlD
Ruxolitinib—DCLK1—nipple—skin cancer	0.000707	0.0107	CbGeAlD
Ruxolitinib—CYP3A4—Vemurafenib—skin cancer	0.000703	0.16	CbGbCtD
Ruxolitinib—JAK1—neck—skin cancer	0.000699	0.0106	CbGeAlD
Ruxolitinib—Myelosuppression—Docetaxel—skin cancer	0.000691	0.0162	CcSEcCtD
Ruxolitinib—CAMK1D—nipple—skin cancer	0.00069	0.0104	CbGeAlD
Ruxolitinib—IRAK1—hair follicle—skin cancer	0.00068	0.0103	CbGeAlD
Ruxolitinib—MKNK2—hair follicle—skin cancer	0.00068	0.0103	CbGeAlD
Ruxolitinib—GRK7—head—skin cancer	0.000678	0.0103	CbGeAlD
Ruxolitinib—Malnutrition—Vismodegib—skin cancer	0.000674	0.0158	CcSEcCtD
Ruxolitinib—DAPK2—nipple—skin cancer	0.000674	0.0102	CbGeAlD
Ruxolitinib—Herpes zoster—Temozolomide—skin cancer	0.000647	0.0152	CcSEcCtD
Ruxolitinib—PLK1—mammalian vulva—skin cancer	0.000644	0.00975	CbGeAlD
Ruxolitinib—CLK2—nipple—skin cancer	0.000628	0.0095	CbGeAlD
Ruxolitinib—ANKK1—head—skin cancer	0.00062	0.00938	CbGeAlD
Ruxolitinib—JAK2—blood vessel—skin cancer	0.000588	0.00889	CbGeAlD
Ruxolitinib—PRKCE—female reproductive system—skin cancer	0.000574	0.00869	CbGeAlD
Ruxolitinib—PLK1—lymphoid tissue—skin cancer	0.000572	0.00866	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00057	0.0134	CcSEcCtD
Ruxolitinib—NUAK2—nipple—skin cancer	0.000565	0.00854	CbGeAlD
Ruxolitinib—RPS6KA6—female reproductive system—skin cancer	0.000552	0.00835	CbGeAlD
Ruxolitinib—PLK1—female reproductive system—skin cancer	0.000552	0.00835	CbGeAlD
Ruxolitinib—Weight decreased—Vemurafenib—skin cancer	0.000541	0.0127	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vismodegib—skin cancer	0.00054	0.0126	CcSEcCtD
Ruxolitinib—PLK3—mammalian vulva—skin cancer	0.000538	0.00814	CbGeAlD
Ruxolitinib—Skin disorder—Vismodegib—skin cancer	0.000535	0.0125	CcSEcCtD
Ruxolitinib—Infestation—Vemurafenib—skin cancer	0.000533	0.0125	CcSEcCtD
Ruxolitinib—Infestation NOS—Vemurafenib—skin cancer	0.000533	0.0125	CcSEcCtD
Ruxolitinib—LRRK2—nipple—skin cancer	0.000524	0.00793	CbGeAlD
Ruxolitinib—BMP2K—neck—skin cancer	0.000523	0.00792	CbGeAlD
Ruxolitinib—PRKG2—head—skin cancer	0.000514	0.00778	CbGeAlD
Ruxolitinib—JAK3—connective tissue—skin cancer	0.000504	0.00763	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—skin cancer	0.000503	0.00761	CbGeAlD
Ruxolitinib—JAK1—connective tissue—skin cancer	0.000501	0.00758	CbGeAlD
Ruxolitinib—GRK1—head—skin cancer	0.00049	0.00742	CbGeAlD
Ruxolitinib—Pancytopenia—Imiquimod—skin cancer	0.000484	0.0113	CcSEcCtD
Ruxolitinib—PRKCE—head—skin cancer	0.00048	0.00726	CbGeAlD
Ruxolitinib—MAP3K7—nipple—skin cancer	0.000476	0.0072	CbGeAlD
Ruxolitinib—JAK1—epithelium—skin cancer	0.000476	0.0072	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Vismodegib—skin cancer	0.000475	0.0111	CcSEcCtD
Ruxolitinib—Fatigue—Vismodegib—skin cancer	0.000475	0.0111	CcSEcCtD
Ruxolitinib—HIPK2—connective tissue—skin cancer	0.000468	0.00708	CbGeAlD
Ruxolitinib—TYK2—nipple—skin cancer	0.000467	0.00707	CbGeAlD
Ruxolitinib—MKNK2—nipple—skin cancer	0.000461	0.00698	CbGeAlD
Ruxolitinib—PLK1—head—skin cancer	0.000461	0.00697	CbGeAlD
Ruxolitinib—RPS6KA6—head—skin cancer	0.000461	0.00697	CbGeAlD
Ruxolitinib—MAST1—head—skin cancer	0.000461	0.00697	CbGeAlD
Ruxolitinib—PLK3—female reproductive system—skin cancer	0.000461	0.00697	CbGeAlD
Ruxolitinib—Infestation NOS—Imiquimod—skin cancer	0.000455	0.0107	CcSEcCtD
Ruxolitinib—Infestation—Imiquimod—skin cancer	0.000455	0.0107	CcSEcCtD
Ruxolitinib—JAK1—skin of body—skin cancer	0.000452	0.00684	CbGeAlD
Ruxolitinib—RET—neck—skin cancer	0.000445	0.00673	CbGeAlD
Ruxolitinib—LTK—female reproductive system—skin cancer	0.000445	0.00673	CbGeAlD
Ruxolitinib—Urinary tract infection—Imiquimod—skin cancer	0.000442	0.0104	CcSEcCtD
Ruxolitinib—DCLK3—head—skin cancer	0.000437	0.00661	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—skin cancer	0.000432	0.00653	CbGeAlD
Ruxolitinib—CAMK1—female reproductive system—skin cancer	0.000431	0.00652	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Imiquimod—skin cancer	0.00043	0.0101	CcSEcCtD
Ruxolitinib—JAK2—nipple—skin cancer	0.000425	0.00643	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—skin cancer	0.000419	0.00634	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—skin cancer	0.000418	0.00633	CbGeAlD
Ruxolitinib—Malnutrition—Vemurafenib—skin cancer	0.000417	0.00976	CcSEcCtD
Ruxolitinib—JAK1—mammalian vulva—skin cancer	0.000413	0.00624	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—skin cancer	0.000413	0.00624	CbGeAlD
Ruxolitinib—Haemoglobin—Imiquimod—skin cancer	0.00041	0.00961	CcSEcCtD
Ruxolitinib—MAP3K3—nipple—skin cancer	0.00041	0.0062	CbGeAlD
Ruxolitinib—ROCK1—epithelium—skin cancer	0.00041	0.0062	CbGeAlD
Ruxolitinib—Haemorrhage—Imiquimod—skin cancer	0.000408	0.00956	CcSEcCtD
Ruxolitinib—CAMK1D—mammalian vulva—skin cancer	0.000403	0.00609	CbGeAlD
Ruxolitinib—Asthenia—Vismodegib—skin cancer	0.000395	0.00925	CcSEcCtD
Ruxolitinib—DAPK2—mammalian vulva—skin cancer	0.000394	0.00596	CbGeAlD
Ruxolitinib—Pruritus—Vismodegib—skin cancer	0.000389	0.00912	CcSEcCtD
Ruxolitinib—PLK3—head—skin cancer	0.000385	0.00582	CbGeAlD
Ruxolitinib—BMPR2—skin of body—skin cancer	0.000379	0.00573	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—skin cancer	0.000375	0.00567	CbGeAlD
Ruxolitinib—TAOK3—nipple—skin cancer	0.000374	0.00565	CbGeAlD
Ruxolitinib—LTK—head—skin cancer	0.000372	0.00562	CbGeAlD
Ruxolitinib—DAPK3—mammalian vulva—skin cancer	0.00037	0.0056	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—skin cancer	0.000369	0.00558	CbGeAlD
Ruxolitinib—CLK2—mammalian vulva—skin cancer	0.000367	0.00555	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—skin cancer	0.000366	0.00554	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—skin cancer	0.000364	0.00551	CbGeAlD
Ruxolitinib—CAMK1—head—skin cancer	0.00036	0.00544	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—skin cancer	0.000356	0.00538	CbGeAlD
Ruxolitinib—Malnutrition—Imiquimod—skin cancer	0.000355	0.00833	CcSEcCtD
Ruxolitinib—JAK1—female reproductive system—skin cancer	0.000353	0.00535	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000352	0.00825	CcSEcCtD
Ruxolitinib—PLK4—female reproductive system—skin cancer	0.000351	0.00531	CbGeAlD
Ruxolitinib—MARK2—head—skin cancer	0.000349	0.00529	CbGeAlD
Ruxolitinib—Pancytopenia—Bleomycin—skin cancer	0.000344	0.00806	CcSEcCtD
Ruxolitinib—STK16—lymphoid tissue—skin cancer	0.000344	0.0052	CbGeAlD
Ruxolitinib—PHKG2—female reproductive system—skin cancer	0.000343	0.00519	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—skin cancer	0.000342	0.00517	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—skin cancer	0.000341	0.00515	CbGeAlD
Ruxolitinib—Bone pain—Docetaxel—skin cancer	0.000338	0.00792	CcSEcCtD
Ruxolitinib—Infection—Vemurafenib—skin cancer	0.000338	0.00792	CcSEcCtD
Ruxolitinib—PRKCE—lymph node—skin cancer	0.000336	0.00508	CbGeAlD
Ruxolitinib—Nervous system disorder—Vemurafenib—skin cancer	0.000333	0.00781	CcSEcCtD
Ruxolitinib—STK16—female reproductive system—skin cancer	0.000332	0.00502	CbGeAlD
Ruxolitinib—TYK2—connective tissue—skin cancer	0.000331	0.00501	CbGeAlD
Ruxolitinib—Skin disorder—Vemurafenib—skin cancer	0.00033	0.00774	CcSEcCtD
Ruxolitinib—HIPK2—female reproductive system—skin cancer	0.00033	0.00499	CbGeAlD
Ruxolitinib—NUAK2—mammalian vulva—skin cancer	0.00033	0.00499	CbGeAlD
Ruxolitinib—Weight decreased—Bleomycin—skin cancer	0.000328	0.00768	CcSEcCtD
Ruxolitinib—MKNK2—connective tissue—skin cancer	0.000327	0.00495	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.000326	0.00763	CcSEcCtD
Ruxolitinib—CLK2—lymphoid tissue—skin cancer	0.000326	0.00492	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—skin cancer	0.000323	0.00489	CbGeAlD
Ruxolitinib—PLK1—lymph node—skin cancer	0.000323	0.00488	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—skin cancer	0.000323	0.00488	CbGeAlD
Ruxolitinib—Pancytopenia—Dactinomycin—skin cancer	0.000321	0.00752	CcSEcCtD
Ruxolitinib—RET—connective tissue—skin cancer	0.000319	0.00482	CbGeAlD
Ruxolitinib—DAPK3—female reproductive system—skin cancer	0.000317	0.00479	CbGeAlD
Ruxolitinib—Neutropenia—Dactinomycin—skin cancer	0.000316	0.0074	CcSEcCtD
Ruxolitinib—ROCK1—lymphoid tissue—skin cancer	0.000316	0.00477	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—skin cancer	0.000314	0.00475	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000312	0.00731	CcSEcCtD
Ruxolitinib—MKNK2—epithelium—skin cancer	0.00031	0.0047	CbGeAlD
Ruxolitinib—Haematuria—Bleomycin—skin cancer	0.000308	0.00722	CcSEcCtD
Ruxolitinib—DYRK1A—lymphoid tissue—skin cancer	0.000308	0.00466	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—skin cancer	0.000307	0.00464	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—skin cancer	0.000306	0.00463	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—skin cancer	0.000304	0.0046	CbGeAlD
Ruxolitinib—RET—epithelium—skin cancer	0.000303	0.00458	CbGeAlD
Ruxolitinib—JAK2—connective tissue—skin cancer	0.000301	0.00456	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.0003	0.00704	CcSEcCtD
Ruxolitinib—TYK2—skin of body—skin cancer	0.000299	0.00453	CbGeAlD
Ruxolitinib—JAK3—head—skin cancer	0.000297	0.00449	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—skin cancer	0.000297	0.00449	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—skin cancer	0.000296	0.00447	CbGeAlD
Ruxolitinib—DCLK1—head—skin cancer	0.000295	0.00447	CbGeAlD
Ruxolitinib—JAK1—head—skin cancer	0.000295	0.00447	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000294	0.00688	CcSEcCtD
Ruxolitinib—Fatigue—Vemurafenib—skin cancer	0.000293	0.00687	CcSEcCtD
Ruxolitinib—Haemoglobin—Bleomycin—skin cancer	0.000291	0.00683	CcSEcCtD
Ruxolitinib—Pancytopenia—Temozolomide—skin cancer	0.00029	0.0068	CcSEcCtD
Ruxolitinib—Haemorrhage—Bleomycin—skin cancer	0.00029	0.00679	CcSEcCtD
Ruxolitinib—CAMK1D—head—skin cancer	0.000288	0.00436	CbGeAlD
Ruxolitinib—Infection—Imiquimod—skin cancer	0.000288	0.00675	CcSEcCtD
Ruxolitinib—PHKG2—head—skin cancer	0.000286	0.00433	CbGeAlD
Ruxolitinib—JAK2—epithelium—skin cancer	0.000286	0.00433	CbGeAlD
Ruxolitinib—Neutropenia—Temozolomide—skin cancer	0.000286	0.0067	CcSEcCtD
Ruxolitinib—Nervous system disorder—Imiquimod—skin cancer	0.000284	0.00666	CcSEcCtD
Ruxolitinib—Skin disorder—Imiquimod—skin cancer	0.000282	0.0066	CcSEcCtD
Ruxolitinib—Weight increased—Temozolomide—skin cancer	0.000278	0.00652	CcSEcCtD
Ruxolitinib—MAP3K7—mammalian vulva—skin cancer	0.000278	0.0042	CbGeAlD
Ruxolitinib—STK16—head—skin cancer	0.000277	0.00419	CbGeAlD
Ruxolitinib—Weight decreased—Temozolomide—skin cancer	0.000276	0.00648	CcSEcCtD
Ruxolitinib—HIPK2—head—skin cancer	0.000276	0.00417	CbGeAlD
Ruxolitinib—TYK2—mammalian vulva—skin cancer	0.000273	0.00413	CbGeAlD
Ruxolitinib—Infestation—Temozolomide—skin cancer	0.000272	0.00638	CcSEcCtD
Ruxolitinib—Infestation NOS—Temozolomide—skin cancer	0.000272	0.00638	CcSEcCtD
Ruxolitinib—JAK2—skin of body—skin cancer	0.000272	0.00412	CbGeAlD
Ruxolitinib—MAP3K19—head—skin cancer	0.00027	0.00408	CbGeAlD
Ruxolitinib—PLK3—lymph node—skin cancer	0.000269	0.00408	CbGeAlD
Ruxolitinib—MKNK2—mammalian vulva—skin cancer	0.000269	0.00407	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—skin cancer	0.000269	0.00407	CbGeAlD
Ruxolitinib—Body temperature increased—Vemurafenib—skin cancer	0.000269	0.0063	CcSEcCtD
Ruxolitinib—Pancytopenia—Fluorouracil—skin cancer	0.000267	0.00627	CcSEcCtD
Ruxolitinib—TAOK3—connective tissue—skin cancer	0.000265	0.00401	CbGeAlD
Ruxolitinib—Urinary tract infection—Temozolomide—skin cancer	0.000265	0.00621	CcSEcCtD
Ruxolitinib—DAPK3—head—skin cancer	0.000265	0.00401	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—skin cancer	0.000265	0.004	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—skin cancer	0.000265	0.004	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—skin cancer	0.000262	0.00397	CbGeAlD
Ruxolitinib—CLK2—head—skin cancer	0.000262	0.00397	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—skin cancer	0.000262	0.00397	CbGeAlD
Ruxolitinib—LTK—lymph node—skin cancer	0.00026	0.00394	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Temozolomide—skin cancer	0.000258	0.00604	CcSEcCtD
Ruxolitinib—ROCK1—head—skin cancer	0.000254	0.00385	CbGeAlD
Ruxolitinib—CAMK1—lymph node—skin cancer	0.000252	0.00381	CbGeAlD
Ruxolitinib—Infestation—Fluorouracil—skin cancer	0.000251	0.00588	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluorouracil—skin cancer	0.000251	0.00588	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Imiquimod—skin cancer	0.00025	0.00587	CcSEcCtD
Ruxolitinib—Fatigue—Imiquimod—skin cancer	0.00025	0.00586	CcSEcCtD
Ruxolitinib—MAP3K2—lymphoid tissue—skin cancer	0.000249	0.00377	CbGeAlD
Ruxolitinib—JAK2—mammalian vulva—skin cancer	0.000248	0.00376	CbGeAlD
Ruxolitinib—DYRK1A—head—skin cancer	0.000248	0.00375	CbGeAlD
Ruxolitinib—BMPR2—head—skin cancer	0.000247	0.00374	CbGeAlD
Ruxolitinib—Haemoglobin—Temozolomide—skin cancer	0.000246	0.00576	CcSEcCtD
Ruxolitinib—MARK2—lymph node—skin cancer	0.000245	0.0037	CbGeAlD
Ruxolitinib—Haemorrhage—Temozolomide—skin cancer	0.000245	0.00573	CcSEcCtD
Ruxolitinib—Urinary tract infection—Fluorouracil—skin cancer	0.000244	0.00572	CcSEcCtD
Ruxolitinib—Asthenia—Vemurafenib—skin cancer	0.000244	0.00572	CcSEcCtD
Ruxolitinib—TYK2—lymphoid tissue—skin cancer	0.000242	0.00367	CbGeAlD
Ruxolitinib—CYP3A4—Docetaxel—skin cancer	0.000241	0.0548	CbGbCtD
Ruxolitinib—Pruritus—Vemurafenib—skin cancer	0.000241	0.00564	CcSEcCtD
Ruxolitinib—MAP3K2—female reproductive system—skin cancer	0.00024	0.00363	CbGeAlD
Ruxolitinib—MAP3K3—mammalian vulva—skin cancer	0.000239	0.00362	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—skin cancer	0.000239	0.00362	CbGeAlD
Ruxolitinib—Epistaxis—Fluorouracil—skin cancer	0.000237	0.00555	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000235	0.00551	CcSEcCtD
Ruxolitinib—TYK2—female reproductive system—skin cancer	0.000234	0.00353	CbGeAlD
Ruxolitinib—Anaemia—Bleomycin—skin cancer	0.000233	0.00547	CcSEcCtD
Ruxolitinib—RET—lymphoid tissue—skin cancer	0.000233	0.00353	CbGeAlD
Ruxolitinib—MKNK2—female reproductive system—skin cancer	0.000231	0.00349	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—skin cancer	0.000231	0.00349	CbGeAlD
Ruxolitinib—Body temperature increased—Imiquimod—skin cancer	0.000229	0.00537	CcSEcCtD
Ruxolitinib—Haemoglobin—Fluorouracil—skin cancer	0.000227	0.00531	CcSEcCtD
Ruxolitinib—TAOK2—lymph node—skin cancer	0.000226	0.00342	CbGeAlD
Ruxolitinib—Haemorrhage—Fluorouracil—skin cancer	0.000225	0.00528	CcSEcCtD
Ruxolitinib—Dizziness—Vemurafenib—skin cancer	0.000225	0.00527	CcSEcCtD
Ruxolitinib—CAMK2G—head—skin cancer	0.000221	0.00334	CbGeAlD
Ruxolitinib—BMP2K—head—skin cancer	0.000221	0.00334	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—skin cancer	0.00022	0.00333	CbGeAlD
Ruxolitinib—LRRK2—head—skin cancer	0.000219	0.00331	CbGeAlD
Ruxolitinib—TAOK3—mammalian vulva—skin cancer	0.000218	0.0033	CbGeAlD
Ruxolitinib—Anaemia—Dactinomycin—skin cancer	0.000218	0.0051	CcSEcCtD
Ruxolitinib—Headache—Vemurafenib—skin cancer	0.000213	0.00499	CcSEcCtD
Ruxolitinib—Malnutrition—Temozolomide—skin cancer	0.000213	0.00499	CcSEcCtD
Ruxolitinib—JAK2—female reproductive system—skin cancer	0.000213	0.00322	CbGeAlD
Ruxolitinib—Asthenia—Imiquimod—skin cancer	0.000208	0.00488	CcSEcCtD
Ruxolitinib—JAK3—lymph node—skin cancer	0.000208	0.00315	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000207	0.00486	CcSEcCtD
Ruxolitinib—DCLK1—lymph node—skin cancer	0.000207	0.00313	CbGeAlD
Ruxolitinib—JAK1—lymph node—skin cancer	0.000207	0.00313	CbGeAlD
Ruxolitinib—PLK4—lymph node—skin cancer	0.000205	0.00311	CbGeAlD
Ruxolitinib—Pruritus—Imiquimod—skin cancer	0.000205	0.00481	CcSEcCtD
Ruxolitinib—MAP3K3—female reproductive system—skin cancer	0.000205	0.0031	CbGeAlD
Ruxolitinib—Infection—Bleomycin—skin cancer	0.000205	0.0048	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—skin cancer	0.000202	0.00305	CbGeAlD
Ruxolitinib—Thrombocytopenia—Bleomycin—skin cancer	0.000202	0.00473	CcSEcCtD
Ruxolitinib—MAP3K2—head—skin cancer	0.000201	0.00304	CbGeAlD
Ruxolitinib—PHKG2—lymph node—skin cancer	0.000201	0.00303	CbGeAlD
Ruxolitinib—DAPK2—lymph node—skin cancer	0.000197	0.00298	CbGeAlD
Ruxolitinib—Anaemia—Temozolomide—skin cancer	0.000197	0.00461	CcSEcCtD
Ruxolitinib—TYK2—head—skin cancer	0.000195	0.00295	CbGeAlD
Ruxolitinib—STK16—lymph node—skin cancer	0.000194	0.00294	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—skin cancer	0.000194	0.00293	CbGeAlD
Ruxolitinib—Pancytopenia—Docetaxel—skin cancer	0.000193	0.00452	CcSEcCtD
Ruxolitinib—HIPK2—lymph node—skin cancer	0.000193	0.00292	CbGeAlD
Ruxolitinib—MKNK2—head—skin cancer	0.000193	0.00291	CbGeAlD
Ruxolitinib—Dizziness—Imiquimod—skin cancer	0.000192	0.00449	CcSEcCtD
Ruxolitinib—Infection—Dactinomycin—skin cancer	0.000191	0.00447	CcSEcCtD
Ruxolitinib—Neutropenia—Docetaxel—skin cancer	0.00019	0.00445	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Dactinomycin—skin cancer	0.000188	0.00441	CcSEcCtD
Ruxolitinib—RET—head—skin cancer	0.000188	0.00284	CbGeAlD
Ruxolitinib—TAOK3—female reproductive system—skin cancer	0.000187	0.00283	CbGeAlD
Ruxolitinib—DAPK3—lymph node—skin cancer	0.000185	0.0028	CbGeAlD
Ruxolitinib—Weight increased—Docetaxel—skin cancer	0.000185	0.00433	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—skin cancer	0.000184	0.00431	CcSEcCtD
Ruxolitinib—CLK2—lymph node—skin cancer	0.000184	0.00278	CbGeAlD
Ruxolitinib—Headache—Imiquimod—skin cancer	0.000182	0.00426	CcSEcCtD
Ruxolitinib—Anaemia—Fluorouracil—skin cancer	0.000181	0.00425	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—skin cancer	0.000181	0.00425	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—skin cancer	0.000181	0.00425	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00018	0.00422	CcSEcCtD
Ruxolitinib—JAK2—head—skin cancer	0.000178	0.00269	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—skin cancer	0.000174	0.00263	CbGeAlD
Ruxolitinib—BMPR2—lymph node—skin cancer	0.000173	0.00262	CbGeAlD
Ruxolitinib—Infection—Temozolomide—skin cancer	0.000173	0.00405	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Docetaxel—skin cancer	0.000171	0.00402	CcSEcCtD
Ruxolitinib—MAP3K3—head—skin cancer	0.000171	0.00259	CbGeAlD
Ruxolitinib—Epistaxis—Docetaxel—skin cancer	0.000171	0.004	CcSEcCtD
Ruxolitinib—Nervous system disorder—Temozolomide—skin cancer	0.00017	0.00399	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Temozolomide—skin cancer	0.00017	0.00399	CcSEcCtD
Ruxolitinib—Skin disorder—Temozolomide—skin cancer	0.000169	0.00396	CcSEcCtD
Ruxolitinib—Fatigue—Dactinomycin—skin cancer	0.000166	0.00388	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—skin cancer	0.000165	0.0025	CbGeAlD
Ruxolitinib—Haemoglobin—Docetaxel—skin cancer	0.000164	0.00383	CcSEcCtD
Ruxolitinib—Body temperature increased—Bleomycin—skin cancer	0.000163	0.00382	CcSEcCtD
Ruxolitinib—Haemorrhage—Docetaxel—skin cancer	0.000163	0.00381	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—skin cancer	0.000159	0.00373	CcSEcCtD
Ruxolitinib—Nervous system disorder—Fluorouracil—skin cancer	0.000157	0.00368	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—skin cancer	0.000157	0.00367	CcSEcCtD
Ruxolitinib—TAOK3—head—skin cancer	0.000156	0.00236	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—skin cancer	0.000155	0.00234	CbGeAlD
Ruxolitinib—BMP2K—lymph node—skin cancer	0.000155	0.00234	CbGeAlD
Ruxolitinib—LRRK2—lymph node—skin cancer	0.000153	0.00232	CbGeAlD
Ruxolitinib—Body temperature increased—Dactinomycin—skin cancer	0.000152	0.00356	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.00015	0.00352	CcSEcCtD
Ruxolitinib—Fatigue—Temozolomide—skin cancer	0.00015	0.00351	CcSEcCtD
Ruxolitinib—Asthenia—Bleomycin—skin cancer	0.000148	0.00346	CcSEcCtD
Ruxolitinib—Pruritus—Bleomycin—skin cancer	0.000146	0.00342	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—skin cancer	0.000142	0.00332	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—skin cancer	0.000141	0.00213	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—skin cancer	0.000139	0.00211	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000138	0.00324	CcSEcCtD
Ruxolitinib—Asthenia—Dactinomycin—skin cancer	0.000138	0.00323	CcSEcCtD
Ruxolitinib—Body temperature increased—Temozolomide—skin cancer	0.000137	0.00322	CcSEcCtD
Ruxolitinib—TYK2—lymph node—skin cancer	0.000137	0.00207	CbGeAlD
Ruxolitinib—MKNK2—lymph node—skin cancer	0.000135	0.00204	CbGeAlD
Ruxolitinib—IRAK1—lymph node—skin cancer	0.000135	0.00204	CbGeAlD
Ruxolitinib—RET—lymph node—skin cancer	0.000132	0.00199	CbGeAlD
Ruxolitinib—Anaemia—Docetaxel—skin cancer	0.000131	0.00307	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluorouracil—skin cancer	0.000127	0.00297	CcSEcCtD
Ruxolitinib—Asthenia—Temozolomide—skin cancer	0.000125	0.00292	CcSEcCtD
Ruxolitinib—JAK2—lymph node—skin cancer	0.000124	0.00188	CbGeAlD
Ruxolitinib—Pruritus—Temozolomide—skin cancer	0.000123	0.00288	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—skin cancer	0.00012	0.00181	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00012	0.00281	CcSEcCtD
Ruxolitinib—Dizziness—Temozolomide—skin cancer	0.000115	0.00269	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—skin cancer	0.000115	0.00269	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—skin cancer	0.000113	0.00266	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—skin cancer	0.000113	0.00265	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—skin cancer	0.000113	0.00265	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—skin cancer	0.000112	0.00263	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—skin cancer	0.000109	0.00165	CbGeAlD
Ruxolitinib—Headache—Temozolomide—skin cancer	0.000109	0.00255	CcSEcCtD
Ruxolitinib—Dizziness—Fluorouracil—skin cancer	0.000106	0.00248	CcSEcCtD
Ruxolitinib—Headache—Fluorouracil—skin cancer	0.0001	0.00235	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—skin cancer	9.98e-05	0.00234	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—skin cancer	9.96e-05	0.00233	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—skin cancer	9.14e-05	0.00214	CcSEcCtD
Ruxolitinib—Asthenia—Docetaxel—skin cancer	8.29e-05	0.00194	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—skin cancer	8.18e-05	0.00192	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—skin cancer	7.64e-05	0.00179	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—skin cancer	7.24e-05	0.0017	CcSEcCtD
Ruxolitinib—CYP3A4—female reproductive system—skin cancer	5.68e-05	0.000859	CbGeAlD
Ruxolitinib—TYK2—Signaling Pathways—PTCH1—skin cancer	7.74e-06	9.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SMO—skin cancer	7.74e-06	9.42e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—IL6—skin cancer	7.68e-06	9.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HRAS—skin cancer	7.67e-06	9.33e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—KRAS—skin cancer	7.63e-06	9.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—KRAS—skin cancer	7.61e-06	9.26e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—skin cancer	7.58e-06	9.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL6—skin cancer	7.56e-06	9.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—HRAS—skin cancer	7.54e-06	9.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTGER4—skin cancer	7.54e-06	9.17e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—HRAS—skin cancer	7.52e-06	9.15e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTCH1—skin cancer	7.51e-06	9.14e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SMO—skin cancer	7.51e-06	9.14e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—NRAS—skin cancer	7.48e-06	9.1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HRAS—skin cancer	7.44e-06	9.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—IL6—skin cancer	7.43e-06	9.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	7.43e-06	9.04e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—HRAS—skin cancer	7.35e-06	8.94e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL6—skin cancer	7.34e-06	8.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTGER4—skin cancer	7.31e-06	8.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—IL6—skin cancer	7.21e-06	8.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FOXO4—skin cancer	7.2e-06	8.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.18e-06	8.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—skin cancer	7.12e-06	8.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	7.11e-06	8.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—NRAS—skin cancer	7.07e-06	8.6e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—NRAS—skin cancer	7.03e-06	8.56e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—skin cancer	7.03e-06	8.56e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TERT—skin cancer	7e-06	8.52e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—NRAS—skin cancer	6.99e-06	8.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.87e-06	8.36e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FOXO4—skin cancer	6.86e-06	8.35e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—KRAS—skin cancer	6.85e-06	8.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—KRAS—skin cancer	6.84e-06	8.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—HRAS—skin cancer	6.82e-06	8.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—BRAF—skin cancer	6.81e-06	8.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERCC2—skin cancer	6.77e-06	8.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—skin cancer	6.76e-06	8.23e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—KRAS—skin cancer	6.72e-06	8.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FOXO4—skin cancer	6.66e-06	8.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—NRAS—skin cancer	6.65e-06	8.1e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—HRAS—skin cancer	6.64e-06	8.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—HRAS—skin cancer	6.59e-06	8.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—BRAF—skin cancer	6.57e-06	8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—skin cancer	6.53e-06	7.95e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—HRAS—skin cancer	6.49e-06	7.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—HRAS—skin cancer	6.47e-06	7.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FOXO4—skin cancer	6.46e-06	7.86e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—KRAS—skin cancer	6.44e-06	7.83e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—NRAS—skin cancer	6.39e-06	7.77e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NRAS—skin cancer	6.36e-06	7.74e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—skin cancer	6.36e-06	7.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TERT—skin cancer	6.35e-06	7.73e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—skin cancer	6.31e-06	7.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—skin cancer	6.21e-06	7.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SHH—skin cancer	6.19e-06	7.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RASA1—skin cancer	6.15e-06	7.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—KRAS—skin cancer	6.08e-06	7.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NRAS—skin cancer	6.05e-06	7.37e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KRAS—skin cancer	6.05e-06	7.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TERT—skin cancer	6.02e-06	7.33e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—KRAS—skin cancer	6.02e-06	7.32e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TERT—skin cancer	5.92e-06	7.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—NRAS—skin cancer	5.9e-06	7.18e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NRAS—skin cancer	5.9e-06	7.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NRAS—skin cancer	5.88e-06	7.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SMO—skin cancer	5.87e-06	7.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTCH1—skin cancer	5.87e-06	7.14e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NRAS—skin cancer	5.85e-06	7.12e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HRAS—skin cancer	5.82e-06	7.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—skin cancer	5.81e-06	7.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—KRAS—skin cancer	5.73e-06	6.97e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—skin cancer	5.72e-06	6.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NRAS—skin cancer	5.71e-06	6.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—skin cancer	5.71e-06	6.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTGER4—skin cancer	5.71e-06	6.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NRAS—skin cancer	5.7e-06	6.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—skin cancer	5.57e-06	6.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—skin cancer	5.56e-06	6.77e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—BRAF—skin cancer	5.54e-06	6.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—skin cancer	5.5e-06	6.7e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KRAS—skin cancer	5.5e-06	6.69e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KRAS—skin cancer	5.47e-06	6.66e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NRAS—skin cancer	5.47e-06	6.66e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—skin cancer	5.47e-06	6.66e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—skin cancer	5.47e-06	6.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NRAS—skin cancer	5.39e-06	6.56e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—skin cancer	5.38e-06	6.55e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—skin cancer	5.24e-06	6.37e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KRAS—skin cancer	5.21e-06	6.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—skin cancer	5.17e-06	6.29e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—skin cancer	5.14e-06	6.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERCC2—skin cancer	5.13e-06	6.25e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—skin cancer	5.11e-06	6.22e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—KRAS—skin cancer	5.08e-06	6.18e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KRAS—skin cancer	5.07e-06	6.18e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—NRAS—skin cancer	5.07e-06	6.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KRAS—skin cancer	5.06e-06	6.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FOXO4—skin cancer	5.04e-06	6.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NRAS—skin cancer	5.04e-06	6.14e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KRAS—skin cancer	5.03e-06	6.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—BRAF—skin cancer	5.03e-06	6.12e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—skin cancer	4.99e-06	6.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—skin cancer	4.95e-06	6.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—skin cancer	4.95e-06	6.02e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—skin cancer	4.92e-06	5.99e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KRAS—skin cancer	4.92e-06	5.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KRAS—skin cancer	4.91e-06	5.97e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—skin cancer	4.89e-06	5.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—skin cancer	4.87e-06	5.92e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—skin cancer	4.86e-06	5.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TERT—skin cancer	4.81e-06	5.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—BRAF—skin cancer	4.77e-06	5.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KRAS—skin cancer	4.71e-06	5.73e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—BRAF—skin cancer	4.69e-06	5.71e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—skin cancer	4.67e-06	5.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—skin cancer	4.66e-06	5.67e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—skin cancer	4.65e-06	5.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KRAS—skin cancer	4.64e-06	5.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—skin cancer	4.64e-06	5.64e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TERT—skin cancer	4.58e-06	5.57e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—skin cancer	4.47e-06	5.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—skin cancer	4.45e-06	5.42e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—skin cancer	4.45e-06	5.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TERT—skin cancer	4.45e-06	5.41e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—skin cancer	4.43e-06	5.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—skin cancer	4.37e-06	5.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—skin cancer	4.34e-06	5.28e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—skin cancer	4.32e-06	5.25e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—skin cancer	4.31e-06	5.25e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TERT—skin cancer	4.31e-06	5.25e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—skin cancer	4.3e-06	5.23e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—skin cancer	4.3e-06	5.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—skin cancer	4.28e-06	5.21e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—skin cancer	4.28e-06	5.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—skin cancer	4.26e-06	5.18e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—skin cancer	4.24e-06	5.16e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—skin cancer	4.18e-06	5.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—skin cancer	4.17e-06	5.07e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—skin cancer	4.13e-06	5.03e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—skin cancer	4.13e-06	5.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—skin cancer	4.13e-06	5.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—skin cancer	4.11e-06	5.01e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—skin cancer	4.1e-06	4.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—skin cancer	4.06e-06	4.94e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—skin cancer	4e-06	4.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—skin cancer	4e-06	4.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—skin cancer	3.99e-06	4.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—skin cancer	3.99e-06	4.86e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—skin cancer	3.94e-06	4.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—skin cancer	3.83e-06	4.66e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLIN2—skin cancer	3.82e-06	4.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BRAF—skin cancer	3.81e-06	4.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—skin cancer	3.78e-06	4.61e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—skin cancer	3.77e-06	4.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—skin cancer	3.75e-06	4.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—skin cancer	3.71e-06	4.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—skin cancer	3.69e-06	4.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—skin cancer	3.68e-06	4.48e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—skin cancer	3.65e-06	4.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—skin cancer	3.63e-06	4.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—skin cancer	3.62e-06	4.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—skin cancer	3.55e-06	4.32e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—skin cancer	3.55e-06	4.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—skin cancer	3.53e-06	4.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—skin cancer	3.53e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—skin cancer	3.52e-06	4.29e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—skin cancer	3.49e-06	4.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—skin cancer	3.48e-06	4.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—skin cancer	3.42e-06	4.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—skin cancer	3.42e-06	4.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—skin cancer	3.39e-06	4.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—skin cancer	3.37e-06	4.1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—skin cancer	3.32e-06	4.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—skin cancer	3.26e-06	3.97e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—skin cancer	3.25e-06	3.95e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—skin cancer	3.22e-06	3.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—skin cancer	3.16e-06	3.85e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—skin cancer	3.16e-06	3.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—skin cancer	3.13e-06	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—skin cancer	3.12e-06	3.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—skin cancer	3.08e-06	3.75e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CSPG4—skin cancer	3.08e-06	3.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—skin cancer	3.03e-06	3.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—skin cancer	3.02e-06	3.68e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—skin cancer	3e-06	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—skin cancer	3e-06	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—skin cancer	3e-06	3.65e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—skin cancer	2.95e-06	3.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—skin cancer	2.95e-06	3.59e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—skin cancer	2.89e-06	3.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—skin cancer	2.86e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—skin cancer	2.84e-06	3.46e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—skin cancer	2.74e-06	3.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—skin cancer	2.72e-06	3.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—skin cancer	2.67e-06	3.25e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—skin cancer	2.67e-06	3.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—skin cancer	2.62e-06	3.19e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—skin cancer	2.59e-06	3.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—skin cancer	2.58e-06	3.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—skin cancer	2.58e-06	3.14e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—skin cancer	2.55e-06	3.1e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—skin cancer	2.54e-06	3.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—skin cancer	2.5e-06	3.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—skin cancer	2.47e-06	3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—skin cancer	2.44e-06	2.97e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—skin cancer	2.44e-06	2.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—skin cancer	2.43e-06	2.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—skin cancer	2.4e-06	2.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—skin cancer	2.39e-06	2.91e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—skin cancer	2.32e-06	2.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—skin cancer	2.31e-06	2.81e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—skin cancer	2.29e-06	2.79e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—skin cancer	2.28e-06	2.77e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—skin cancer	2.26e-06	2.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—skin cancer	2.23e-06	2.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—skin cancer	2.21e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—skin cancer	2.21e-06	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—skin cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—skin cancer	2.16e-06	2.62e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—skin cancer	2.15e-06	2.61e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—skin cancer	2.1e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—skin cancer	2.09e-06	2.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—skin cancer	2.08e-06	2.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—skin cancer	2.06e-06	2.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—skin cancer	2.06e-06	2.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—skin cancer	1.99e-06	2.42e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—skin cancer	1.96e-06	2.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—skin cancer	1.9e-06	2.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—skin cancer	1.9e-06	2.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—skin cancer	1.85e-06	2.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—skin cancer	1.82e-06	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—skin cancer	1.75e-06	2.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—skin cancer	1.74e-06	2.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—skin cancer	1.69e-06	2.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—skin cancer	1.68e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—skin cancer	1.68e-06	2.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—skin cancer	1.67e-06	2.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—skin cancer	1.64e-06	2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—skin cancer	1.62e-06	1.97e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—skin cancer	1.6e-06	1.94e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—skin cancer	1.57e-06	1.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—skin cancer	1.55e-06	1.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—skin cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—skin cancer	1.44e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—skin cancer	1.28e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—skin cancer	1.23e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ERCC2—skin cancer	1.22e-06	1.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—skin cancer	1.17e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—skin cancer	7.29e-07	8.87e-06	CbGpPWpGaD
